Beneficiaries

InPharma consists of 11 Beneficiaries who will employ the 13 Early Stage Resarchers (ESRs) uniting world-leading academic research groups and pharma companies on their common search for better drug formulation processes which lead to safer and more efficient drugs for patients while simultaneously eradicating animal testing from the process and reducing development costs.

Academic Beneficiaries

B1: University College Cork, School of Pharmacy (UCC), Ireland

Team Leader: Prof. Brendan Griffin

B2: Fraunhofer Gesellschaft zur Förderung der angewandten Forschung E.V., Department of Translational Medicine and Pharmacology (TMP) (Fraunhofer IME), Germany

Team Leader: Prof. Jennifer Dressman

B3: National and Kapodistrian University of Athens, Department of Pharmacy, Section of Pharmaceutical Technology (NKUA), Greece

Team Leader: Prof. Christos Reppas

B4: University of Southern Denmark, Department of Physics, Chemistry & Pharmacy (SDU), Denmark

Team Leader: Prof. Annette Bauer-Brandl

B5: University of Applied Sciences & Arts Northwestern Switzerland, Institute of Pharma Technology (FHNW)

Team Leader: Prof. Martin Kuentz

Industry Beneficiaries

B6: AstraZeneca AB, Early Product Development (AZ), Sweden

Team Leader: Sara Carlert

B7: Bayer AG, Pharmaceutical R&D (Bayer), Germany

Team Leader: Dr. André Dallmann

B8: Janssen Pharmaceutica NV, Drug Product Development (Janssen), Belgium

Team Leader: Dr. Rene Holm

B9: F. Hoffmann- La Roche AG, Pharmaceutical R&D (Roche), Switzerland

Team Leader: Dr. Nicole Wyttenbach

B10: Solvias AG, Solid-State Development (Solvias), Switzerland

Team Leader: Dr. Rolf Hilfiker

B11: Zentiva K.S., Drug Product Development (Zentiva), Czech Republic

Team Leader: Dr. Josef Beranek